Published in Hepatol Int on January 01, 2011
Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol (2012) 0.99
Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med (2014) 0.94
Emerging antivirals for the treatment of hepatitis B. World J Gastroenterol (2014) 0.84
Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B. World J Gastroenterol (2012) 0.81
Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Clin Mol Hepatol (2013) 0.81
Molecular and clinical aspects of hepatitis D virus infections. World J Virol (2012) 0.81
Therapeutic advances in the management of chronic hepatitis B infection. Ther Adv Chronic Dis (2013) 0.79
Long-term treatment efficacy and safety of clevudine therapy in naïve patients with chronic hepatitis B. Gut Liver (2012) 0.78
Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol (2017) 0.75
Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients. Hepat Mon (2013) 0.75
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat (2004) 13.18
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
Hepatitis B virus infection. N Engl J Med (2008) 6.92
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology (2001) 2.51
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol (2001) 1.98
[Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases]. Korean J Hepatol (2009) 1.54
Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother (1996) 1.42
Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology (2007) 1.33
Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology (2009) 1.32
Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology (2007) 1.21
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat (2006) 1.09
Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol (2010) 1.07
Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol (2009) 1.06
Clevudine myopathy in patients with chronic hepatitis B. J Hepatol (2009) 1.05
Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol (2010) 0.99
Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B. Liver Int (2010) 0.99
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci U S A (2003) 0.92
[Efficacy of 48-week clevudine therapy for chronic hepatitis B]. Korean J Hepatol (2009) 0.92
Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients. Hepatol Res (2009) 0.90
Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study. Antivir Ther (2009) 0.89
Clevudine demonstrates potent antiviral activity in naïve chronic hepatitis B patients. Intervirology (2009) 0.86
Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B. J Korean Med Sci (2010) 0.86
Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antivir Ther (2008) 0.85
Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs (2008) 0.82
Technique for the early detection of drug-resistant HBV DNA during antiviral therapy. Intervirology (2008) 0.82
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology (2012) 2.44
Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol (2004) 2.12
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology (2008) 2.11
Can endoscopic resection be applied for early stage ampulla of Vater cancer? Gastrointest Endosc (2006) 2.06
Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer (2005) 1.86
Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter (2011) 1.82
Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. AJR Am J Roentgenol (2005) 1.79
Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol (2006) 1.79
Hemostatic efficacy and clinical outcome of endoscopic treatment of Dieulafoy's lesions: comparison of endoscopic hemoclip placement and endoscopic band ligation. Gastrointest Endosc (2011) 1.68
Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.66
The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci (2009) 1.65
[Risk factors for development and recurrence of peptic ulcer disease]. Korean J Gastroenterol (2010) 1.59
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol (2008) 1.58
A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int (2013) 1.57
Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol (2005) 1.57
Detection rate of Helicobacter pylori against a background of atrophic gastritis and/or intestinal metaplasia. J Clin Gastroenterol (2007) 1.55
[Changes in the profiles of causative agents and antibiotic resistance rate for spontaneous bacterial peritonitis: an analysis of cultured microorganisms in recent 12 years]. Korean J Hepatol (2007) 1.54
Evaluation of esophageal varices on liver computed tomography: receiver operating characteristic analyses of the performance of radiologists and endoscopists. J Gastroenterol Hepatol (2009) 1.53
[Assessment of factors affecting the accuracy of endoscopic ultrasonography in T2 stage gastric cancer]. Korean J Gastroenterol (2008) 1.51
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol (2012) 1.47
Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol (2010) 1.44
Toxocariasis and ingestion of raw cow liver in patients with eosinophilia. Korean J Parasitol (2008) 1.44
[Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B]. Korean J Hepatol (2010) 1.43
Comparison of malignant potential between serrated adenomas and traditional adenomas. J Gastroenterol Hepatol (2007) 1.42
[Effects of proton pump inhibitors in asthmatics with gastroesophageal reflux disease]. Korean J Gastroenterol (2011) 1.42
[Clinical features and predictive factors of acute hepatitis A complicated with acute kidney injury]. Korean J Gastroenterol (2010) 1.41
Incidence and risk factors of irritable bowel syndrome in community subjects with culture-proven bacterial gastroenteritis. Korean J Gastroenterol (2012) 1.40
Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter (2012) 1.40
Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg (2005) 1.39
Hepatitis a in Korea: epidemiological shift and call for vaccine strategy. Intervirology (2008) 1.39
[Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively]. Korean J Gastroenterol (2009) 1.39
[Inhibition of in vitro hepatitis B virus replication by lentivirus-mediated short-hairpin RNA against HBx]. Korean J Hepatol (2009) 1.38
Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol (2010) 1.36
Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology (2007) 1.33
[Recent etiology and clinical features of acute viral hepatitis in a single center of Korea]. Korean J Hepatol (2007) 1.32
Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. J Hepatol (2003) 1.32
Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients. AJR Am J Roentgenol (2007) 1.26
Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest (2005) 1.25
Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis (2009) 1.24
Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol (2006) 1.24
Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. Gastrointest Endosc (2004) 1.23
The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter (2008) 1.23
Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol (2010) 1.23
Learning curves for colonoscopy: a prospective evaluation of gastroenterology fellows at a single center. Gut Liver (2010) 1.22
Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology (2007) 1.21
Diagnosis of pelvic congestion syndrome using transabdominal and transvaginal sonography. AJR Am J Roentgenol (2004) 1.19
Clinical diagnosis of primary epiploic appendagitis: differentiation from acute diverticulitis. J Clin Gastroenterol (2002) 1.17
Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol (2007) 1.15
Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol (2006) 1.15
[The age-specific seroprevalence of hepatitis A virus antibody in Korea]. Korean J Hepatol (2007) 1.15
Clinical characteristics and treatment outcomes of 3 subtypes of achalasia according to the chicago classification in a tertiary institute in Korea. J Neurogastroenterol Motil (2013) 1.14
Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol (2007) 1.14
[A case of benign schwannoma in the porta hepatis]. Korean J Gastroenterol (2006) 1.14
Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. J Gastroenterol Hepatol (2010) 1.12
The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter (2008) 1.12
Transmission of Toxocara canis via ingestion of raw cow liver: a cross-sectional study in healthy adults. Korean J Parasitol (2012) 1.11